semax

russian nootropic. approved there, not here. for focus, stroke recovery, and cognitive decline. real mechanism, thin US trials.

tier B · focus · Russia '82 stroke registry

verdict

Russian nootropic. approved there since the 1990s. BDNF upregulation within 30 minutes of an intranasal dose, effect persists 24+ hours.

if you're asking how much to trust the Russian trial record — dozens of trials, three approved indications, decades of prescription use without a serious safety signal. the stroke and cognitive-impairment trials were controlled. the same shape Western regulators would recognize, just published in Russian and never re-run for FDA. modern English-language work (default mode network neuroimaging, post-ischemic gene expression studies) has moved the story from folklore into measurable biology.

if you're asking what Semax actually does — upregulates BDNF mRNA in the hippocampus and cortex within 30 minutes of an intranasal dose. also modulates dopamine and serotonin, inhibits enkephalinase, binds melanocortin receptors. the original design point was 'the cognitive effects of ACTH without the cortisol.' community users report sharper focus and faster recall inside the first few doses, building over 1-2 weeks. side effects: occasional nasal irritation.

if you came in expecting US clinical access — none. the FDA's PCAC review on July 24, 2026 is a US compounding-status inflection point, not drug approval. for now: more rigorously studied than nootropic culture suggests, less validated than Russian regulators treat it. the regulatory geography is the ceiling, not the evidence base.

based on published evidence and disclosed clinical practice. not medical advice.

why B-tier

B-tier because the evidence base is real but geographically and linguistically constrained. Russian regulatory approval for three indications, two decades of clinical use, confirmed BDNF mechanism. Held back from A-tier because Western clinical replication is limited and most primary literature requires Russian-language fluency to read. FDA's 503A process could change the U.S. compounding lane, but that would not be drug approval.

the core tension

Semax has more clinical human data than almost any other 'nootropic peptide': dozens of Russian trials, regulatory approval for ischemic stroke, listing on Russia's Vital & Essential Drugs List. The catch isn't evidence thinness. It's language and geography. Most of the research is in Russian journals, under Russian regulatory standards, and the FDA is only now reviewing it (July 2026, for compounding use).

what it is

a synthetic heptapeptide built on the ACTH(4-10) fragment with a Pro-Gly-Pro stability tail. the name is Russian shorthand for seven amino acids. approved in Russia for ischemic stroke, cognitive disorders, and optic nerve atrophy. on the Vital and Essential Drugs List since 2011. intranasal in the clinical formulation.

what it does

upregulates BDNF mRNA in the hippocampus and cortex within 30 minutes of an intranasal dose. effect persists 24-plus hours. also modulates dopamine and serotonin, inhibits enkephalinase, binds melanocortin receptors. the cognitive effects of ACTH without the cortisol. that was the design point.

origin

Institute of Molecular Genetics at the Russian Academy of Sciences. led by Nikolai Myasoedov with Igor Ashmarin at Moscow State University. first published 1991. the same lab later built Selank with the same Pro-Gly-Pro trick. IMG remains the center of Russian cognitive-peptide research.

why researchers are interested

more human clinical data than almost any other nootropic peptide. dozens of Russian trials, three approved indications, decades of prescription use without a serious safety signal. community users describe sharper focus, faster recall, less mental fatigue inside the first few doses, building over 1 to 2 weeks. side effects: occasional nasal irritation. that is roughly it.

does it work

the BDNF mechanism is real. the Russian stroke and cognitive-impairment trials were controlled, the same shape Western regulators would recognize, just published in Russian. modern English-language work, default mode network neuroimaging and post-ischemic gene expression studies, has moved the story from folklore into measurable biology. held back from A-tier by language and regulatory geography, not evidence thinness. the FDA's PCAC review on July 24, 2026 is a U.S. compounding-status inflection point, not drug approval. for now: more rigorously studied than nootropic culture suggests, less validated than Russian regulators treat it.

claims vs the data

• rapidly upregulates BDNF in hippocampus and cortex — supported — Dolotov et al. 2006 showed single intranasal dose elevates BDNF mRNA within 30 minutes, effect persisting 24h. Multiple subsequent studies confirm. This is established pharmacology.
• improves cognitive function in healthy users — partially true — Russian trials in healthy subjects show attention and working-memory improvements. Western replication is limited. Community reports are consistent but self-selected.
• improves stroke recovery outcomes — supported — Gusev et al. 2005 and subsequent Russian trials in ischemic stroke patients show improved neurological recovery when administered within 6 hours of onset. Basis for Russian regulatory approval.
• does not elevate cortisol despite being an ACTH fragment — supported — ACTH(4-10) was specifically chosen because it retains cognitive effects without the hormonal (1-24) sequence. Dissociation was a design goal, confirmed in pharmacology studies.
• treats ADHD — weak — some Russian clinical use for attention disorders but no FDA-grade evidence. Community adoption for ADHD is off-label even in Russia. Mechanism is plausible (dopaminergic modulation) but not validated.
• favorable safety signal in studied intranasal use — partially true — decades of Russian clinical use show no serious safety signals. Long-term Western safety data is thin. Side effect profile in trials has been consistently mild (occasional nasal irritation from the spray).

key facts

• molecular formula: C37H51N9O10S
• molecular weight: 813.9 Da
• amino acids: 7
• half-life: minutes in plasma; effects persist for hours due to CNS penetration and BDNF induction cascade
• type: heptapeptide (ACTH 4-10 analog + PGP extension)
• CAS: 80714-61-0
• 2011 Russian Vital & Essential Drugs List
• July 2026 FDA 503A review date
• 30 min time to measurable BDNF upregulation
• 3 Russian-approved indications

frequently asked questions

What is Semax?

Semax is a synthetic heptapeptide derived from ACTH 4-10 (adrenocorticotropic hormone). Developed at the Institute of Molecular Genetics in Moscow in the 1980s-90s. Registered in Russia in intranasal formulations for ischemic stroke and selected neurocognitive or ophthalmic indications. It is not FDA-approved in the United States.

What does Semax do?

Modulates BDNF (brain-derived neurotrophic factor) expression and has demonstrated neuroprotective, cognitive-enhancing, and mood-stabilizing effects in Russian clinical trials and research. Community users commonly report improved focus, memory performance, and resilience to mental fatigue within weeks of regular use.

How is Semax typically administered?

Semax is approved for clinical use in Russia as an intranasal formulation, with dosing determined by prescribing physicians under that regulatory regime. There is no FDA-approved dosing protocol in the United States. This site does not provide dosing guidance for compounds not approved by the FDA.

What are the side effects of Semax?

Side effect reports are usually mild: nasal irritation and occasional transient headache. Russian label contexts still matter: acute psychiatric disorders, anxiety disorders, seizure history, pregnancy, lactation, and age restrictions are not casual footnotes. Long-term U.S.-style safety data is limited.

Is Semax FDA approved?

No. Semax is not FDA-approved in the United States. It is registered in Russia for selected intranasal clinical uses. FDA's July 2026 review concerns possible 503A compounding status, not drug approval.

How much does Semax cost?

No US clinical retail price exists. On the research-chemical market it is inexpensive, varying by strength (commonly 5-10mg). Nasal-drop formulations from Russian pharmacies are available via international import at varying prices.

related peptides

• selank — sister peptide from same Russian lab
• dihexa — Western nootropic with weaker clinical base
• pt-141 — similar story: melanocortin-family peptide, accidental cognitive effects

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.